Difference between revisions of "Part:BBa K1722002"

Line 12: Line 12:
 
So in this study, we choose hTERT as a promoter to specifically recognise cancer cells to express the downstream effector. We constructed hTERT and GFP in the same plasmid and inserted the plasmid into T24, a bladder cancer cell line, to test if hTERT can be activated inside the cell. Luckily, we saw green fluorescent light using confocal laser scanning microscopy.
 
So in this study, we choose hTERT as a promoter to specifically recognise cancer cells to express the downstream effector. We constructed hTERT and GFP in the same plasmid and inserted the plasmid into T24, a bladder cancer cell line, to test if hTERT can be activated inside the cell. Luckily, we saw green fluorescent light using confocal laser scanning microscopy.
  
hTERT is 454bp in length. <b>Fig. 2</b> shows the DNA sequence of hTERT is successfully amplified by PCR from psi-Check2 vector. From this electrophoretogram, we can see the brightness of hTERT PCR product is rather high compared with DNA Marker, which indicates that the PCR product of hTERT is in a high concerntration.
+
hTERT is 454bp in length. <b>Fig. 1</b> shows the DNA sequence of hTERT is successfully amplified by PCR from psi-Check2 vector. From this electrophoretogram, we can see the brightness of hTERT PCR product is rather high compared with DNA Marker, which indicates that the PCR product of hTERT is in a high concerntration.
  
 
<html>
 
<html>
<figure style="text-align: center"><img style="width:30%" src="https://static.igem.org/mediawiki/2015/1/14/Tert_pcr3.png"/><figcaption style="text-align:center"><b>Figure 2.</b> Electrophoretic analysis of PCR produution of hTERT promoter from psi-Check2. (1:PCR production 2:DL2000 DNA Marker)</figcaption></figure>
+
<figure style="text-align: center"><img style="width:30%" src="https://static.igem.org/mediawiki/2015/1/14/Tert_pcr3.png"/><figcaption style="text-align:center"><b>Figure 1.</b> Electrophoretic analysis of PCR produution of hTERT promoter from psi-Check2. (1:PCR production 2:DL2000 DNA Marker)</figcaption></figure>
 +
 
 +
</html>
 +
 
 +
After ligating hTERT and pSB1C3, we transfected the new pasmid being constructed into Ecoli and selected those Ecoli with Chl resistence. Using these Ecoli as templet, we amplified hTERT from pSB1C3,<b>(Fig. 2)</b> which means we had successfly construacted the pSB1C3-hTERT plasmid.
 +
<html>
 +
 
 +
<figure style="text-align: center"><img style="width:50%" src="https://static.igem.org/mediawiki/2015/f/f7/Tert_pcr%E9%AA%8C%E8%AF%81.png"/><figcaption style="text-align:center"><b>Figure 2.</b> Electrophoretic analysis of PCR product of hTERT promoter from pSB1C3. (1:DL2000 DNA Marker 2:PCR product)</figcaption></figure>
  
 
</html>
 
</html>

Revision as of 08:22, 4 September 2015

hTERT is a tumor specific promoter.

hTERT is a tumor specific promoter which is short for human telomerase reverse transcriptase. The human telomerase enzyme complex consists of human telomerase reverse transcriptase(TERT), telomerase RNA(TR) and dyskerin(DKCI).[1] This class of enzyme can catalyze the adding of (TTAGGG)n to the 3' end of telomeres to elongate the telomeres, thus prolonging cells' life. Researches show that the telomerase activity is based mostly on the expression level of TERT instead of that of TR and TEP. High telomerase activities are tested on most high proliferation cells such as tumor cells and stem cells. The core region of hTERT promoter lies on the 181bp sequence upstream of transcriptional start site, involving several binding sites for transcriptional factors, like sp1, cmyc, p53 and mad1. Researches show that hTERT promoters are activated in tumor cells that are telomerase positive while being inhibited in normal cells that are telomerase negative, which indicates that hTERT promoter may specifically target at tumor cells. Gu et al found the transcriptional activity of CMV promoter was almost 500 times higher than that of hTERT promoter in normal cells. However, the magnification shrinked to only 5-20 in tumor cells.

So in this study, we choose hTERT as a promoter to specifically recognise cancer cells to express the downstream effector. We constructed hTERT and GFP in the same plasmid and inserted the plasmid into T24, a bladder cancer cell line, to test if hTERT can be activated inside the cell. Luckily, we saw green fluorescent light using confocal laser scanning microscopy.

hTERT is 454bp in length. Fig. 1 shows the DNA sequence of hTERT is successfully amplified by PCR from psi-Check2 vector. From this electrophoretogram, we can see the brightness of hTERT PCR product is rather high compared with DNA Marker, which indicates that the PCR product of hTERT is in a high concerntration.

Figure 1. Electrophoretic analysis of PCR produution of hTERT promoter from psi-Check2. (1:PCR production 2:DL2000 DNA Marker)

After ligating hTERT and pSB1C3, we transfected the new pasmid being constructed into Ecoli and selected those Ecoli with Chl resistence. Using these Ecoli as templet, we amplified hTERT from pSB1C3,(Fig. 2) which means we had successfly construacted the pSB1C3-hTERT plasmid.

Figure 2. Electrophoretic analysis of PCR product of hTERT promoter from pSB1C3. (1:DL2000 DNA Marker 2:PCR product)

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Design Notes

We designed the following primers and amplified hTERT promoter from the vector psi-Check2:Up: CCGGAATTCGGCACCTCCCTCGGGTTAG Down: TGCACTGCAGACTAGTCGCGTGGGTGGCCG. By incorporating these primers into hTERT promoter, the promoter is flanked by the iGEM prefix and suffix after amplification.

Source

The telomerase reverse transcriptase promoter can be found in human cancer cells. In our experiment, we got the part from Shenzhen Second People's Hospital. Additionally, the verification of our system's function was also carried out in Shenzhen Second People's Hospital.

References

[1] Cohen S, Graham M, Lovrecz G, Bache N, Robinson P, Reddel R (2007). "Protein composition of catalytically active human telomerase from immortal cells". Science 315 (5820): 1850–3.